Affiliation:
1. Department of Chemistry Kurukshetra University, Kurukshetra Thanesar 136119 Haryana India
2. Department of Chemistry Maharishi Markandeshwar (Deemed to be University), Mullana Ambala 133207 Haryana India
3. Department of Botanical & Environmental Sciences Guru Nanak Dev University, Amritsar Amritsar 143005 Punjab India
4. Department of Chemistry National Institute of Technology (NIT), Kurukshetra Thanesar 136119 Haryana India
Abstract
AbstractA novel series of bis([1,2,4]triazolo)[4,3‐a][4′,3′‐c] quinazolines derivatives 2 a–2 o has been synthesis in good to excellent yields (74–86 %) under mild reaction conditions via bis(trifluoroacetoxy)iodobenzene (PIFA) mediated oxidative‐cyclization of corresponding 2,4‐bis(2‐(E)‐arylidenehydrazinyl) quinazolines 1 a–1 o. Formation of the targeted compounds has been supported using various spectroscopic tools (IR, 1H & 13 C‐NMR) and HRMS analysis. These bis([1,2,4]triazolo)[4,3‐a][4′,3′‐c] quinazolines derivatives were biologically screened for their antiproliferative activities against MCF‐7 cancer cells. Results indicate that among all synthesized derivatives, 3,7‐bis (4‐chlorophenyl) bis([1,2,4]triazolo)[4,3‐a : 4′,3′‐c]quinazoline (2 d) and 3,7‐bis(3‐methoxyphenyl)bis([1,2,4]triazolo)[4,3‐a : 4′,3′‐c]quinazoline (2 j) displayed uppermost cytotoxicity efficacy with GI50 value of 106.30 μM and 108.56 μM respectively. Furthermore, molecular docking studies have been carried out to investigate possible binding modes between active sites of the protein (PDB ID: 3 U6 J) and the target compounds. In addition to these results, ADME (adsorption, distribution, metabolism, excretion) analysis has also been carried out to study the pharmacokinetic properties of the targeted compounds.
Funder
Kurukshetra University
Sophisticated Analytical Instrument Facility
Panjab University
Malaviya National Institute of Technology, Jaipur